AGMB
AgomAb Therapeutics NV
8.60$
-1.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 64.8% | 70.4% | 81.4% | 84.2% | 78.9% | |
| 63.8% | 27.4% | 71.5% | 83.1% | 56.2% | |
| – | – | – | – | 75.8% | |
| – | – | – | – | 3.1% | |
| 10.3% | 8.5% | 5.0% | 4.2% | 6.6% | |
| 23.9% | 19.9% | 11.7% | 9.7% | 15.4% | |
| 49.6% | 34.4% | 11.6% | 8.9% | 14.8% | |
| 40.1% | 29.4% | 6.4% | 4.4% | 12.1% | |
| – | – | – | – | 0.2% | |
| 1.3% | 3.9% | 4.0% | 2.9% | 5.0% | |
| 0.8% | – | – | – | – | |
| 50.4% | 65.6% | 88.4% | 91.1% | 85.2% | |
| -53.4% | -60.8% | -42.5% | -57.8% | -118.2% | |
| – | 35.9% | 21.2% | 17.6% | 31.7% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.